[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Powell JL, Bock KA, Gentry JK, White WC, Ronnett BM: Metastatic endocervical adenocarcinoma presenting as a virilizing ovarian mass during pregnancy. Obstet Gynecol; 2002 Nov;100(5 Pt 2):1129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic endocervical adenocarcinoma presenting as a virilizing ovarian mass during pregnancy.
  • BACKGROUND: We report a case of metastatic endocervical adenocarcinoma that presented as a virilizing ovarian mass in a young pregnant woman and simulated a primary ovarian endometrioid tumor.
  • The ovarian tumor, initially interpreted as a primary ovarian endometrioid carcinoma, was demonstrated to represent metastatic endocervical endometrioid adenocarcinoma based on detection of human papillomavirus 16 (HPV-16) deoxyribonucleic acid in the tumor by in situ hybridization.
  • The hysterectomy specimen demonstrated an endocervical adenocarcinoma associated with adenocarcinoma in situ that also contained HPV-16.
  • CONCLUSION: Human papillomavirus is considered an etiological agent in the development of endocervical adenocarcinomas, having been demonstrated in greater than 90% of tumors.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / secondary. Pregnancy Complications, Neoplastic. Uterine Cervical Neoplasms / pathology


2. Farré X, Guillén-Gómez E, Sánchez L, Hardisson D, Plaza Y, Lloberas J, Casado FJ, Palacios J, Pastor-Anglada M: Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer; 2004 Dec 20;112(6):959-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors.
  • These 2 antisera, along with a previously characterized antibody that specifically recognizes the high-affinity Na-dependent concentrative NT, hCNT1, have been used to analyze, using a tissue array approach, NT expression in gynecologic cancers (90 ovarian, 80 endometrial and 118 uterine cervix carcinomas).
  • Human CNT1 was not detected in 33% and 39% of the ovarian and uterine cervix carcinomas, respectively, whereas hENT1 and hENT2 expression was significantly retained in a high percentage of tumors (91% and 96% for hENT1, 84% and 98% for hENT2, in ovarian and cervix carcinomas, respectively).
  • In ovarian cancer, the loss of all 3 NT proteins was a more common event in the clear cell histologic subtype than in the serous, mucinous and endometrioid histotypes.
  • In uterine cervix tumors, the loss of expression of hCNT1 was significantly associated with the adenocarcinoma subtype.
  • Moreover, NT expression is related to the type of gynecologic tumor and its specific subtype, hCNT1 protein loss being highly correlated with poor prognosis histotypes.
  • Since hCNT1, hENT1 and hENT2 recognize fluoropyrimidines as substrates, but with different affinities, this study anticipates high variability in drug uptake efficiency in solid tumors.
  • [MeSH-major] Carcinoma / chemistry. Equilibrative Nucleoside Transporter 1 / analysis. Equilibrative-Nucleoside Transporter 2 / analysis. Genital Neoplasms, Female / chemistry. Membrane Transport Proteins / analysis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma, Clear Cell / chemistry. Adenocarcinoma, Mucinous / chemistry. Antibodies, Neoplasm / analysis. Carcinoma, Endometrioid / chemistry. Carcinoma, Squamous Cell / chemistry. Cystadenocarcinoma, Serous / chemistry. Endometrial Neoplasms / chemistry. Female. Gene Expression Regulation, Neoplastic. Humans. Immune Sera. Ovarian Neoplasms / chemistry. Uterine Cervical Neoplasms / chemistry

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15386342.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Equilibrative Nucleoside Transporter 1; 0 / Equilibrative-Nucleoside Transporter 2; 0 / Immune Sera; 0 / Membrane Transport Proteins; 0 / cif nucleoside transporter
  •  go-up   go-down


3. Aoki Y, Sato T, Watanabe M, Sasaki M, Tsuneki I, Tanaka K: Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. Gynecol Oncol; 2001 Jun;81(3):496-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma.
  • OBJECTIVE: The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma.
  • Those eligible included patients with previously untreated stage IB, II, or III adenocarcinoma with good performance status.
  • CONCLUSIONS: Intraarterial neoadjuvant chemotherapy effectively reduced tumor size in patients with locally advanced cervical adenocarcinoma; however, a survival advantage was not clear.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / surgery. Cisplatin / administration & dosage. Dose-Response Relationship, Drug. Female. Fluorouracil / administration & dosage. Humans. Hysterectomy. Infusions, Intra-Arterial. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging


Advertisement
4. Ajit D, Gavas S, Jagtap S, Chinoy RF: Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy. Acta Cytol; 2009 Jul-Aug;53(4):383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytodiagnostic problems in cervicovaginal smears from symptomatic breast cancer patients on tamoxifen therapy.
  • Of 4 patients with a cytodiagnosis of atypical glandular changes, 2 had negative histology; 1 each had a uterine leiomyoma and endometrial hyperplasia.
  • Of the 6 cases reported as adenocarcinoma, 3 were histologically confirmed, and the others were false positives.
  • Conversely, 1 false negative case histologically was an endometrioid carcinoma.
  • To avoid diagnostic errors, cervicovaginal smears should be repeated after discontinuing tamoxifen treatment.
  • [MeSH-major] Cervix Uteri / pathology. Tamoxifen / adverse effects. Uterine Cervical Neoplasms / pathology. Vagina / pathology. Vaginal Neoplasms / pathology. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Diagnosis, Differential. False Positive Reactions. Female. Humans. Middle Aged






Advertisement